Updated:
Eleven Biotherapeutics
Altasciences is a biotechnology company developing protein therapeutics for eye diseases. The company focuses on cytokines, signaling molecules that...
Overview
Altasciences is a biotechnology company developing protein therapeutics for eye diseases. The company focuses on cytokines, signaling molecules that contribute to inflammation in eye diseases. Altasciences is conducting research on diseases of the front and back of the eye, including dry eye disease, allergic conjunctivitis, diabetic macular edema, and uveitis.
General information
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
Cambridge, MA, United States
Frequently asked questions
What was Eleven Biotherapeutics' area of research focus?
Eleven Biotherapeutics was focused on protein engineering to develop novel biologics for oncology indications. The company's platform was designed to create proteins with improved drug-like properties, targeting cancer pathways through a pipeline of therapeutic candidates.
How was Eleven Biotherapeutics funded?
The company was funded through venture capital investments and strategic partnerships with larger pharmaceutical companies. Specific investors and partners are not publicly documented in detail.
What is 'Altss' and why is it cited here?
Altss is the research entity providing this profile. In cases where direct public sources are unavailable, Altss relies on its own research records to fill gaps, marked as '(Altss estimate)' or 'public record' as appropriate.
Did Eleven Biotherapeutics achieve commercial-stage products?
Public records do not indicate that Eleven Biotherapeutics brought any commercial-stage products to market. The company's focus remained on preclinical and clinical development, and its pipeline status is not currently documented in widely available sources.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: